Overview
News
Technologies
Salaries
Products
People
Jobs
Growth
Financials
Overview
Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.
News
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers PharmExec
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
Read more
Report
Regeneron's Semaglutide Plus Trevogrumab Combo Demonstrates Superior Fat Loss with Reduced Muscle Wasting in Obesity Trial PharmExec
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves lean mass and enhances fat loss, offering a potential advancement in obesity treatment.
Read more
Report
Report
Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program PharmExec
Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments beginning in August.
Read more
Report
Jobs
No jobs available at this time.